COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA

Author(s)

Baker TM1, Paly VF1, Sabater J2, Okoro T2, Kotapati S2, Briggs A3
1ICON Health Economics & Epidemiology, New York City, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3University of Glasgow, Glasgow, UK

OBJECTIVES:  

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN124

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×